How AI is rewriting future of cancer care

By Ojo Ademola

Cancer has long been one of humanity’s most formidable adversaries, speaking in volumes that echo through families, communities, and nations. Its burden is heavy, its reach global, and its consequences often devastating. Yet, in this digital age, a profound shift is underway. Artificial intelligence—once a distant promise—is now emerging as a practical, clinical force capable of reshaping how cancer is detected, diagnosed, treated, and ultimately defeated. The convergence of computational power, biomedical science, and global health innovation is creating a new frontier where cancer’s voice can be muted, its pathways disrupted, and its dominance challenged. This article explores how AI is transforming oncology with assertiveness, clarity, and evidence, and why this transformation matters profoundly for both advanced health systems and the Global South.

AI and the new era of early detection

Early detection remains the most decisive factor in cancer survival. The World Health Organization estimates that up to 50 per cent of cancers can be prevented or treated effectively when detected early. Artificial intelligence is now pushing this frontier further than any human-led system has ever achieved.

In radiology, deep-learning models are demonstrating diagnostic sensitivity that rivals—and in some cases surpasses—expert radiologists. A landmark study published in Nature reported that an AI system reduced false negatives in breast cancer screening by nearly 9 per cent compared with human specialists. Similar breakthroughs are emerging in lung cancer detection, where AI can identify malignant nodules at stages too subtle for the human eye.

Pathology is undergoing a parallel revolution. Whole-slide imaging powered by AI can analyse millions of cells within seconds, identifying malignant transformations with remarkable precision. What once required days of laboratory processing can now be completed in minutes, accelerating clinical decision-making and reducing patient anxiety.

In low-resource settings, AI-enabled smartphone diagnostics are proving transformative. Cervical cancer screening using mobile cameras and machine-learning classifiers is already deployed in India and Kenya, offering low-cost, high-accuracy alternatives to traditional cytology. These innovations demonstrate that early detection is no longer a privilege of advanced health systems; it is becoming a global possibility.

Precision treatment in the age of machine intelligence

The complexity of cancer lies in its heterogeneity. No two tumours are identical, and no two patients respond to treatment in the same way. Artificial intelligence is now enabling clinicians to navigate this complexity with unprecedented clarity.

AI-driven genomic analysis allows oncologists to understand the molecular architecture of tumours in exquisite detail. Machine-learning models can identify actionable mutations, predict therapeutic responses, and recommend targeted treatments tailored to each patient’s biology. This is the essence of precision oncology: treatment that is not merely reactive but strategically personalised.

Radiotherapy is also being transformed. AI-guided systems can optimise radiation dosage with millimetre accuracy, reducing damage to surrounding tissues and improving patient outcomes. In chemotherapy, predictive algorithms are helping clinicians anticipate adverse reactions, enabling safer and more effective treatment plans.

Immunotherapy—one of the most promising frontiers in cancer care—is benefiting significantly from AI. Algorithms can analyse immune profiles, forecast treatment responses, and identify patients most likely to benefit from specific immunotherapeutic agents.

This reduces trial-and-error approaches and enhances therapeutic success.

The cumulative effect is profound: AI is not replacing oncologists, but it is augmenting their capabilities, sharpening their judgement, and expanding their therapeutic reach.

Drug discovery at digital speed

Traditional drug discovery is notoriously slow, often requiring 10 to 15 years from concept to approval. Artificial intelligence is collapsing this timeline dramatically.

Generative AI models can design novel anti-cancer molecules within weeks, exploring chemical spaces far beyond human imagination. Protein-folding algorithms, such as AlphaFold, have accelerated the identification of therapeutic targets, enabling researchers to understand cancer-related proteins with unprecedented accuracy.

Virtual clinical trials—powered by AI simulations—allow researchers to test drug responses across thousands of hypothetical patients before entering human trials. This reduces costs, enhances safety, and increases the likelihood of success.

Several AI-designed cancer drugs are already in Phase I trials, marking a historic shift in pharmaceutical innovation.

The implications are enormous: faster drug development, lower costs, and more targeted therapies that align with the biological realities of modern oncology.

The Global South: Where AI’s Promise Meets Urgent Need

Cancer is increasingly recognised as a major public health challenge in Africa, Asia, and Latin America. The Global South faces rising incidence rates, limited specialist availability, and infrastructural constraints that hinder early detection and treatment. Artificial intelligence offers a pathway to leapfrog traditional barriers.

AI-powered tele-oncology platforms are connecting rural clinics to urban specialists, reducing diagnostic delays and improving treatment coordination. Low-cost AI diagnostic tools are enabling frontline health workers to identify cancers earlier, even in settings without advanced laboratory infrastructure.

Local-language cancer chatbots are improving awareness, reducing stigma, and guiding patients toward appropriate care pathways. AI-driven triage systems are helping emergency departments prioritise cancer patients more effectively, reducing mortality associated with delayed intervention.

Crucially, the Global South is not merely adopting AI innovations; it is beginning to produce them. African researchers are developing machine-learning models tailored to local epidemiology, while Asian innovators are creating AI-powered screening tools designed for high-population contexts. This shift aligns directly with the argument that digital health solutions must be contextual, equitable, and locally relevant.

Ethics, Governance, and the Imperative of Responsible AI

The rise of AI in oncology brings immense promise, but it also demands robust governance. Data privacy, algorithmic bias, and regulatory oversight are critical considerations.

Cancer datasets often reflect demographic imbalances, which can lead to biased algorithms if not carefully managed. Ethical frameworks must ensure that AI systems serve all populations equitably, particularly those historically underrepresented in clinical research.

Regulatory bodies are beginning to respond. The United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) is developing guidelines for AI-driven medical devices, while the European Union’s AI Act introduces stringent requirements for high-risk health applications. These frameworks are essential for ensuring safety, transparency, and accountability.

Sustainability is another concern. Digital health projects must be designed for long-term viability, with clear strategies for maintenance, training, and integration into existing health systems. AI must not become another short-lived innovation; it must be embedded into the fabric of modern healthcare.

What People Should Be Doing Now

At this pivotal moment, individuals, families, and communities must become active participants in the digital transformation of cancer care. People should prioritise regular screening, embrace digital diagnostic tools where available, and demand that their healthcare providers integrate AI‑enhanced systems that improve accuracy and speed. Citizens must also cultivate digital health literacy, learning how AI‑driven platforms, symptom trackers, and tele‑oncology services can support early intervention. Beyond personal vigilance, society must advocate for equitable access to these technologies, ensuring that breakthroughs do not remain confined to elite hospitals but reach every district, every clinic, and every vulnerable population. The future of cancer care will reward those who act early, stay informed, and insist that innovation becomes a shared public good rather than a privileged advantage.

Conclusion

Artificial intelligence is not a distant promise in oncology; it is a present reality reshaping how cancer is understood, detected, and treated. From early detection to precision therapy, from accelerated drug discovery to global health innovation, AI is redefining the contours of cancer care with assertiveness and clarity. The digital age is offering humanity a new set of tools—powerful, scalable, and transformative—capable of silencing cancer’s once-dominant voice.

Yet this transformation must be guided by ethical governance, equitable access, and sustained investment. The future of cancer care will not be determined solely by algorithms, but by the collective will to deploy them responsibly and inclusively. In this emerging landscape, the fusion of human expertise and machine intelligence offers a profound promise: a world where cancer’s grip is weakened, its pathways disrupted, and its impact diminished. The digital age is not merely observing cancer; it is confronting it—and increasingly, it is winning.

• Continued on www.thesun.ng

• Ademola, is First African Professor of Cybersecurity and Information Technology Management, Global Education Advocate, Chartered Manager, UK Digital Journalist, Strategic Advisor & Prophetic Mobiliser for National Transformation, public intellectual, and African governance thinker and General Evangelist of CAC Nigeria and Overseas.